ILMN
Illumina, Inc. · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 1.67M | $453.36M | n/a | n/a |
| Q2 2026 | 164 | +8 | 117.28M | $20.62B | +11 | −2 |
| Q1 2026 | 158 | -5 | 113.90M | $14.03B | +5 | −11 |
| Q4 2025 | 162 | 0 | 124.91M | $16.38B | +2 | −1 |
| Q3 2025 | 23 | -1 | 78.13M | $7.41B | +1 | −3 |
| Q2 2025 | 22 | 0 | 71.58M | $6.83B | +1 | −1 |
| Q1 2025 | 19 | 0 | 39.00M | $3.09B | +1 | −1 |
| Q4 2024 | 19 | 0 | 37.37M | $4.99B | +2 | −2 |
| Q3 2024 | 18 | 0 | 20.75M | $2.70B | +1 | −1 |
| Q2 2024 | 18 | n/a | 22.19M | $2.32B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Ninety One UK Ltd | 1.36M | +37920.0% | $372.20M | 0.8% | ▲ Add | 2 | SEC ↗ |
| 2 | TD Waterhouse Canada Inc. | 127.36K | +599.2% | $33.89M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 3 | Wealth Enhancement Advisory… | 102.33K | -5.1% | $24.86M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 4 | Assenagon Asset Management S.A. | 81.86K | -70.8% | $22.40M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 837 holders, 154.80M shares, $18.58B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 7.50K sh · $1.63M
Director · 11.35K sh · $2.49M
Director · 100.65K sh · $21.98M
Director · 13.26K sh · $2.87M
Director · 9.96K sh · $2.21M
Director · 6.66K sh · $1.47M
Director · 13.72K sh · $3.01M
Director · 9.72K sh · $2.12M
Director · 14.20K sh · $3.08M
Director · 8.44K sh · $1.82M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology